- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the
- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - - Webcast will be held May 27 th, 2026, at 8:00 AM EDT - DURHAM, N.C. --(BUSINESS WIRE)--May 21, 2026-- Precision BioSciences, Inc.
– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young
- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial
- Arkansas Children’s Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 24, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the
- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 22, 2026-- Precision BioSciences, Inc.
- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 8, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in
- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - - Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 11, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices
– Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment in a humanized DMD mouse model demonstrates improvements in muscle pathology and biomarkers of muscle damage – – PBGENE-DMD
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 9, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial
– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar to feature expert insights on potential clinical utility of PBGENE-DMD for patients with Duchenne